Certain Meds Not Cost-Effective for First-Line Therapy of T2DM
MONDAY, Oct. 3, 2022 (HealthDay News) — Sodium-glucose cotransporter-2 (SGTL2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists are effective as first-line therapy for patients with type 2 diabetes, but are not cost-effective, accordin…
Learn MoreGlucose-Lowering Meds Compared for Use With Metformin in T2DM
MONDAY, Oct. 3, 2022 (HealthDay News) — For patients with type 2 diabetes receiving metformin, the addition of glargine and liraglutide is more effective than glimepiride and sitagliptin for achieving and maintaining target glycated hemoglobin levels…
Learn MoreOptimizing Lifestyle Factors May Cut T2DM Risk Despite GDM History
FRIDAY, Sept. 30, 2022 (HealthDay News) — For women with a history of gestational diabetes mellitus, there is an inverse association between number of optimal modifiable factors and an incrementally lower risk for type 2 diabetes, according to a stud…
Learn MoreBionic Pancreas Bests Standard Care for Glycemic Control in T1DM
THURSDAY, Sept. 29, 2022 (HealthDay News) — Reduction in glycated hemoglobin level is greater with use of a bionic pancreas compared with standard care in children and adults with type 1 diabetes, according to a study published in the Sept. 29 issue …
Learn More‘Bionic Pancreas’ Could Make Life Easier for People With Type 1 Diabetes
THURSDAY, Sept. 29, 2022 (HealthDay News) — A new technology dubbed the “bionic pancreas” may beat standard treatment in helping people with type 1 diabetes control their blood sugar levels, a clinical trial has found.Among adults and children with t…
Learn MoreLa COVID aumenta las probabilidades de diabetes tipo 1 de un niño en un 72 por ciento
MARTES, 27 de septiembre de 2022 (HealthDay News) — Los niños que contraen la COVID-19 podrían experimentar un ligero aumento en el riesgo de desarrollar diabetes tipo 1, sugiere un estudio reciente.Los investigadores encontraron que, de más de 285,0…
Learn MoreDoubling of Type 1 Diabetes Cases Anticipated Globally From 2021 to 2040
TUESDAY, Sept. 27, 2022 (HealthDay News) — The burden of type 1 diabetes (T1D) globally is expected to increase rapidly between 2021 and 2040, according to a study published Sept. 13 in The Lancet Diabetes & Endocrinology.Gabriel A. Gregory, M.D., fr…
Learn MoreCOVID Infection Raises a Child’s Odds for Type 1 Diabetes by 72%
TUESDAY, Sept. 27, 2022 (HealthDay News) — Children who fall ill with COVID-19 may have a slightly increased risk of developing type 1 diabetes, a new study suggests.Researchers found that of more than 285,000 children with COVID, 0.04% were diagnose…
Learn MoreSemaglutide Reduces 10-Year Risk for T2D in Obese Persons
TUESDAY, Sept. 27, 2022 (HealthDay News) — Semaglutide reduces the 10-year risk for type 2 diabetes (T2D) in obese or overweight individuals, and sustained treatment is needed to maintain this risk reduction, according to a study presented at the ann…
Learn MoreEl daño en la visión podría comenzar mucho antes del diagnóstico de diabetes tipo 2
VIERNES, 23 de septiembre de 2022 (HealthDay News) — El daño nervioso es un efecto secundario común de la diabetes tipo 2, y podría comenzar en los ojos mucho antes de que la afección de diagnostique, sugiere una nueva investigación.En este estudio, …
Learn More